Symbols / RCKT $3.55 -1.93% Rocket Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NGM
RCKT Chart
About

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 385.42M
Enterprise Value 221.37M Income -223.12M Sales —
Book/sh 2.56 Cash/sh 1.74 Dividend Yield —
Payout 0.00% Employees 202 IPO —
P/E — Forward P/E -2.65 PEG —
P/S — P/B 1.39 P/C —
EV/EBITDA -1.02 EV/Sales — Quick Ratio 6.25
Current Ratio 6.38 Debt/Eq 8.97 LT Debt/Eq —
EPS (ttm) -2.01 EPS next Y -1.34 EPS Growth —
Revenue Growth — Earnings 2026-05-07 ROA -33.29%
ROE -60.27% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 108.57M
Shs Float 86.97M Short Float 26.20% Short Ratio 4.64
Short Interest — 52W High 8.26 52W Low 2.19
Beta 0.57 Avg Volume 3.42M Volume 2.29M
Target Price $8.48 Recom Buy Prev Close $3.62
Price $3.55 Change -1.93%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.48
Mean price target
2. Current target
$3.55
Latest analyst target
3. DCF / Fair value
$-17.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.55
Low
$3.00
High
$16.00
Mean
$8.48

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main B of A Securities Buy → Buy $9
2026-03-27 main Chardan Capital Buy → Buy $11
2026-03-02 main Goldman Sachs Sell → Sell $3
2026-02-27 main Cantor Fitzgerald Overweight → Overweight $10
2025-11-18 main B of A Securities Buy → Buy $8
2025-11-18 down JP Morgan Overweight → Underweight $263
2025-10-14 main Chardan Capital Buy → Buy $11
2025-10-03 main Leerink Partners Market Perform → Market Perform $7
2025-08-20 up B of A Securities Neutral → Buy $10
2025-08-20 main Chardan Capital Buy → Buy $11
2025-08-11 main Chardan Capital Buy → Buy $11
2025-08-08 main Cantor Fitzgerald Overweight → Overweight $8
2025-07-25 main Canaccord Genuity Buy → Buy $10
2025-07-25 down B of A Securities Buy → Neutral $4
2025-07-24 main Chardan Capital Buy → Buy $12
2025-07-24 main Needham Hold → Hold —
2025-06-17 main UBS Buy → Buy $5
2025-06-03 main Canaccord Genuity Buy → Buy $11
2025-05-28 main B of A Securities Buy → Buy $9
2025-05-28 main BMO Capital Outperform → Outperform $8
News
RSS: Latest RCKT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 MILITELLO JOHN Officer — 1,157 $3.34 $3,862
2026-02-18 WILSON MARTIN General Counsel — 1,376 $3.34 $4,593
2026-02-18 SHAH GAURAV D Chief Executive Officer — 5,990 $3.34 $19,995
2026-02-13 MILITELLO JOHN Officer and Treasurer — 3,726 $3.31 $12,341
2026-02-13 WILSON MARTIN General Counsel — 12,253 $3.31 $40,582
2026-02-13 SHAH GAURAV D Chief Executive Officer — 12,279 $3.31 $40,668
2026-02-11 MILITELLO JOHN Officer — 29,982 $0.00 $0
2026-02-11 WILSON MARTIN General Counsel — 311,813 $0.00 $0
2026-02-11 SHAH GAURAV D Chief Executive Officer — 286,028 $0.00 $0
2026-02-11 RIZVI SYED ALI-AAMIR M.D. Officer — 61,963 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
228.52
-16.36%
273.20
+5.22%
259.66
+16.00%
223.84
Research And Development
142.01
-17.07%
171.24
-8.10%
186.34
+12.55%
165.57
Selling General And Administration
86.50
-15.16%
101.96
+39.07%
73.32
+24.75%
58.77
General And Administrative Expense
86.50
-15.16%
101.96
+39.07%
73.32
+24.75%
58.77
Other Gand A
86.50
-15.16%
101.96
+39.07%
73.32
+24.75%
58.77
Other Operating Expenses
—
—
—
-0.50
Total Expenses
228.52
-16.36%
273.20
+5.22%
259.66
+16.00%
223.84
Operating Income
-228.52
+16.36%
-273.20
-5.22%
-259.66
-16.00%
-223.84
Total Operating Income As Reported
-231.75
+15.17%
-273.20
-5.22%
-259.66
-15.74%
-224.34
EBITDA
-210.21
+15.06%
-247.49
-4.59%
-236.62
-10.73%
-213.69
Normalized EBITDA
-206.98
+16.37%
-247.49
-4.59%
-236.62
-10.73%
-213.69
Reconciled Depreciation
11.03
+17.60%
9.38
+32.08%
7.10
+13.28%
6.27
EBIT
-221.23
+13.87%
-256.86
-5.39%
-243.72
-10.80%
-219.95
Total Unusual Items
-3.23
0.00
—
—
Total Unusual Items Excluding Goodwill
-3.23
0.00
—
—
Special Income Charges
-3.23
0.00
—
—
Restructuring And Mergern Acquisition
3.23
0.00
—
—
Net Income
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Pretax Income
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Net Non Operating Interest Income Expense
8.62
-40.36%
14.46
+2.81%
14.06
+610.30%
1.98
Interest Expense Non Operating
1.89
+0.27%
1.89
+0.59%
1.88
-1.78%
1.91
Net Interest Income
8.62
-40.36%
14.46
+2.81%
14.06
+610.30%
1.98
Interest Expense
1.89
+0.27%
1.89
+0.59%
1.88
-1.78%
1.91
Interest Income Non Operating
10.52
-35.67%
16.34
+2.55%
15.94
+309.85%
3.89
Interest Income
10.52
-35.67%
16.34
+2.55%
15.94
+309.85%
3.89
Other Income Expense
-3.23
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Net Income From Continuing Operation Net Minority Interest
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Net Income From Continuing And Discontinued Operation
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Net Income Continuous Operations
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Normalized Income
-219.89
+15.02%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Net Income Common Stockholders
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Diluted EPS
-2.01
+26.37%
-2.73
+6.51%
-2.92
+10.43%
-3.26
Basic EPS
-2.01
+26.37%
-2.73
+6.51%
-2.92
+10.43%
-3.26
Basic Average Shares
111.12
+17.21%
94.81
+12.85%
84.01
+23.27%
68.15
Diluted Average Shares
111.12
+17.21%
94.81
+12.85%
84.01
+23.27%
68.15
Diluted NI Availto Com Stockholders
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Line Item Trend 2022-12-31
Total Assets
551.81
Current Assets
364.06
Cash Cash Equivalents And Short Term Investments
356.39
Cash And Cash Equivalents
140.52
Other Short Term Investments
215.88
Prepaid Assets
—
Other Current Assets
7.67
Total Non Current Assets
187.75
Net PPE
77.64
Gross PPE
86.74
Accumulated Depreciation
-9.09
Properties
0.00
Machinery Furniture Equipment
15.61
Other Properties
70.54
Leases
0.59
Goodwill And Other Intangible Assets
64.88
Goodwill
39.15
Other Intangible Assets
25.72
Investments And Advances
43.28
Non Current Prepaid Assets
0.61
Other Non Current Assets
1.34
Total Liabilities Net Minority Interest
62.12
Current Liabilities
39.17
Payables And Accrued Expenses
26.65
Payables
0.60
Other Payable
0.60
Current Accrued Expenses
26.06
Pensionand Other Post Retirement Benefit Plans Current
10.01
Current Debt And Capital Lease Obligation
2.51
Current Capital Lease Obligation
2.51
Total Non Current Liabilities Net Minority Interest
22.95
Long Term Debt And Capital Lease Obligation
20.36
Long Term Capital Lease Obligation
20.36
Other Non Current Liabilities
2.60
Stockholders Equity
489.69
Common Stock Equity
489.69
Capital Stock
0.79
Common Stock
0.79
Preferred Stock
0.00
Share Issued
79.12
Ordinary Shares Number
79.12
Treasury Shares Number
0.00
Additional Paid In Capital
1,203.07
Retained Earnings
-713.77
Gains Losses Not Affecting Retained Earnings
-0.36
Treasury Stock
0.05
Other Equity Adjustments
-0.36
Total Equity Gross Minority Interest
489.69
Total Capitalization
489.69
Working Capital
324.89
Invested Capital
489.69
Total Debt
22.87
Capital Lease Obligations
22.87
Net Tangible Assets
424.81
Tangible Book Value
424.81
Interest Payable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-190.01
+9.40%
-209.72
-7.60%
-194.92
-9.42%
-178.14
Cash Flow From Continuing Operating Activities
-190.01
+9.40%
-209.72
-7.60%
-194.92
-9.42%
-178.14
Net Income From Continuing Operations
-223.12
+13.77%
-258.75
-5.35%
-245.59
-10.70%
-221.86
Depreciation Amortization Depletion
11.03
+17.60%
9.38
+32.08%
7.10
+13.28%
6.27
Depreciation
11.03
+17.60%
9.38
+32.08%
7.10
+13.28%
6.27
Depreciation And Amortization
11.03
+17.60%
9.38
+32.08%
7.10
+13.28%
6.27
Other Non Cash Items
—
—
—
—
Stock Based Compensation
37.06
-15.62%
43.92
+11.46%
39.41
+27.08%
31.01
Asset Impairment Charge
0.26
0.00
-100.00%
0.89
+275.00%
0.24
Operating Gains Losses
—
-1.88
-415.38%
-0.36
—
Gain Loss On Investment Securities
—
-1.88
-415.38%
-0.36
—
Change In Working Capital
-8.26
-245.71%
5.67
-58.97%
13.82
+127.49%
6.08
Change In Prepaid Assets
2.09
+416.04%
-0.66
-124.54%
2.69
+174.98%
-3.59
Change In Payables And Accrued Expense
-10.35
-270.61%
6.07
-40.21%
10.15
+4.89%
9.67
Change In Other Current Liabilities
-0.00
-100.38%
0.27
-72.99%
0.98
+19720.00%
-0.01
Investing Cash Flow
103.77
-21.21%
131.71
+234.30%
-98.07
-41.46%
-69.33
Cash Flow From Continuing Investing Activities
103.77
-21.21%
131.71
+234.30%
-98.07
-41.46%
-69.33
Net PPE Purchase And Sale
-0.44
+92.49%
-5.86
+64.41%
-16.47
-91.11%
-8.62
Purchase Of PPE
-0.44
+92.49%
-5.86
+64.41%
-16.47
-91.11%
-8.62
Capital Expenditure
-0.44
+92.49%
-5.86
+64.41%
-16.47
-91.11%
-8.62
Net Investment Purchase And Sale
104.21
-24.25%
137.57
+268.60%
-81.59
+21.11%
-103.43
Purchase Of Investment
-276.55
-12.47%
-245.89
+37.10%
-390.92
-3.88%
-376.33
Sale Of Investment
380.76
-0.70%
383.45
+23.96%
309.33
+13.35%
272.89
Net Business Purchase And Sale
—
0.00
0.00
-100.00%
42.73
Financing Cash Flow
0.15
-99.92%
185.74
-10.87%
208.40
+34.20%
155.29
Cash Flow From Continuing Financing Activities
0.15
-99.92%
185.74
-10.87%
208.40
+34.20%
155.29
Net Common Stock Issuance
-0.07
-100.04%
185.74
-10.87%
208.39
+34.20%
155.29
Common Stock Payments
-0.07
0.00
0.00
+100.00%
-0.05
Repurchase Of Capital Stock
-0.07
0.00
0.00
+100.00%
-0.05
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.01
0.00
Net Other Financing Charges
0.21
—
—
—
Changes In Cash
-86.10
-179.93%
107.72
+227.36%
-84.58
+8.24%
-92.18
Beginning Cash Position
165.00
+188.07%
57.28
-59.62%
141.86
-39.39%
234.04
End Cash Position
78.90
-52.18%
165.00
+188.07%
57.28
-59.62%
141.86
Free Cash Flow
-190.45
+11.66%
-215.59
-1.99%
-211.39
-13.19%
-186.76
Interest Paid Supplemental Data
—
—
—
0.00
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-6.97
+13.56%
-8.07
+20.65%
-10.17
-7688.06%
0.13
Common Stock Issuance
0.00
-100.00%
185.74
-10.87%
208.39
+34.16%
155.34
Issuance Of Capital Stock
0.00
-100.00%
185.74
-10.87%
208.39
+34.16%
155.34
Sale Of Business
—
0.00
0.00
-100.00%
42.73
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category